Dania Therapeutics ApS: Financial statements 2024
CVR: 42523925
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
Dania Therapeutics ApS (CVR 42523925) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK -8,836,654 and a net result of DKK -9,556,855 compared with DKK -8,721,963 the year before. Equity in the 2024 report amounted to DKK -10,373,332. The company had 1 employee in the financial year.
- Revenue
- DKK 0
- Gross Profit
- DKK -8,836,654
- Profit/Loss
- DKK -9,556,855
- Equity
- DKK -10,373,332
- Total Assets
- DKK 7,136,312
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | 0 | -8.8M | -9.6M | -10.4M | 1 |
| 2023 | 0 | -9.2M | -8.7M | -1.2M | 1 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
Dania Therapeutics ApS has published its annual report for 2023. Revenue came to DKK 0, and the net result was DKK -8,721,963.
As of January 15, 2024, Kristian Helin has joined the board of directors of Dania Therapeutics ApS.
As of January 15, 2024, Kim Andersen has left the board of directors of Dania Therapeutics ApS.
About Dania Therapeutics ApS
Dania Therapeutics ApS is a Danish company of the type Anpartsselskab based in København K, founded in 2021. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Karin Absalonsen. The board consists of Karin Absalonsen (chair), Kristian Helin and Michael Manchuan Li. The company is owned by Kristian Helin, Hannibal Innovation ApS and Vernalis (R&D) Limited. The company has 1 employee (2026). In 2025, the company reported a gross profit of DKK -3,390,139 and a net result of DKK -5,039,754 compared with DKK -9,556,855 the year before. Equity in the 2025 report amounted to DKK -15,413,086.